Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Wes Yin"'
Publikováno v:
Drugs in Context, Pp 1-14 (2016)
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 m
Externí odkaz:
https://doaj.org/article/ed0cccff9bed421392946efa58855a26
Autor:
Seanna Vine, Joanna P. MacEwan, Katharine Batt, Desi Peneva, Steve Sison, Wes Yin, Clara Chen
Publikováno v:
Leukemia & Lymphoma. 59:941-949
This study characterized the costs of multiple myeloma (MM) during first-line (1L), second-line (2L) and third-line (3L) treatment from the US payer perspective. Patients with ≥2 outpatient or ≥1 inpatient claims with a primary MM diagnosis and 1
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 23:206-213
Metastatic pancreatic cancer (mPC) is associated with low survival, with less than 10% of patients surviving 5 years. Recent therapies improve survival outcomes where few alternative therapies exist, but few economic analyses measure the value of sur
Publikováno v:
Drugs in Context, Pp 1-14 (2016)
Drugs in Context
Drugs in Context
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 m
Autor:
Joanna P, MacEwan, John J, Sheehan, Wes, Yin, Jacqueline, Vanderpuye-Orgle, Jeffrey, Sullivan, Desi, Peneva, Iftekhar, Kalsekar, Anne L, Peters
Publikováno v:
The American journal of managed care. 23(4)
This study examined the relationship between medication adherence, cost sharing measured as out-of-pocket spending, and total annual spending in Medicare beneficiaries with type 2 diabetes (T2D) to evaluate whether pharmacy cost-sharing programs have
Publikováno v:
The American journal of managed care. 23(1)
To measure the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes (MDS).Retrospective study of patients diagnosed with MDS in the Surveillance, Epidemiology and End Results Program (SEER) regis
Publikováno v:
Value in Health. 18(3)
Autor:
Seanna Vine, Wes Yin, Manan Shah, Joanna P. MacEwan, Katharine Batt, Clara Chen, Steve Sison, Desi Peneva
Publikováno v:
Blood. 126:2100-2100
Background: The substantial improvement in clinical outcomes for patients with multiple myeloma (MM) conferred by proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and bisphosphonates is associated with an increased financial burden on the
Autor:
Manan Shah, Seanna Vine, Katharine Batt, Clara Chen, Wes Yin, Desi Peneva, Joanna P. MacEwan, Steve Sison
Publikováno v:
Blood. 126:2116-2116
Background: Since 2005, treatment (TX) for patients with multiple myeloma (MM) has been revolutionized by the introduction of new agents that have demonstrated improved clinical outcomes. However, growing constraints on healthcare resources make it i
Publikováno v:
Blood. 124:2608-2608
Cancer survival has improved much since the 1970s, particularly for non-Hodgkin's lymphoma, breast, and colon cancer (Pulte, Arch Int Med 2008; Espey, Cancer 2007; Breen JNCI 2001). Yet some argue that newer treatments offer minimal survival gains at